What if the timing of treatment could change everything? CMTA is funding a new study to find the optimal window for treating CMT1A and CMT1E; and to discover how to tell if it's working.
Pharmacologic Increase of cGMP for the Treatment of CMT1B/1E Neuropathy
With CMTA support of $225,720, researchers led by Maurizio D’Antonio, PhD, at Ospedale San Raffaele...
CMTA Advances Drug Repurposing with an Additional $225,720 Investment in CMT1B and CMT1E Research
CMTA is investing $225,720 to expand drug repurposing research into CMT1B and CMT1E, building on ongoing CMT1A research targeting shared disease mechanisms.
CMTA-STAR Alliance Partner Vanda Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for CMT2S Therapy Candidate
CMTA Strategy to Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has announced that the U.S. Food...
Is Spinal Fluid the Way to Gene Therapy in CMT? What a Decade of Research Reveals
Most kinds of CMT come from a problem in a single gene. Repairing that faulty...
CMTA Leading the Way in CMT1A
CMTA is leading a coordinated CMT1A research strategy that connects disease models, drug development, biomarkers, delivery science, and clinical infrastructure to accelerate new treatments.
CMTA research takes the stage at PNS
PNS 2026 showcased CMTA's role in advancing CMT research across the translational pipeline, from biomarkers and natural history studies to clinical trials, therapeutic development, and the scientific collaborations driving progress.
CMTA Expands Preclinical Toolbox with New CMT1A Assay
CMTA expands its Preclinical Toolbox with a new CMT1A assay, providing researchers with a human-relevant platform to evaluate potential therapies earlier in drug development.
What 465 People with CMT1A Want Researchers to Know
Results from a patient survey conducted by CMTA, CMT France, and Nervosave Therapeutics highlight what matters most to people living with CMT1A.
Cycle Pharmaceuticals Stops Clinical Studies of Govorestat
On April 17, Cycle Pharmaceuticals announced it is halting all govorestat clinical studies, including the INSPIRE Phase III Open Label Extension and Early Access Programs.
